New insider activity at Iradimed ( (IRMD) ) has taken place on February 13, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Director Monty Allen has trimmed his stake in Iradimed, selling 1,000 shares of the company’s stock in a transaction valued at $100,250, according to the latest disclosed trade.
Recent Updates on IRMD stock
Iradimed shares were driven by strong Q4 results, with record revenue growth, expanding EPS, and high, stable gross margins, which prompted analysts to raise price targets based on higher forward estimates and confidence in the company’s execution. The anticipated upside from the higher‑priced 3870 MRI‑compatible pump, its large U.S. replacement opportunity, and guidance implying a path to a higher 2026 revenue run rate further supported more optimistic valuations, despite acknowledged execution and margin risks during the product transition.
Spark’s Take on IRMD Stock
According to Spark, TipRanks’ AI Analyst, IRMD is a Outperform.
IRMD scores well primarily due to strong financial performance (high margins, minimal leverage) and supportive technicals (clear uptrend with positive momentum). The elevated P/E meaningfully tempers the score, while the latest earnings call adds support via raised guidance and continued record revenue, partially offset by higher opex and international regulatory delays.
To see Spark’s full report on IRMD stock, click here.
More about Iradimed
YTD Price Performance: 5.96%
Average Trading Volume: 78,624
Technical Sentiment Signal: Buy
Current Market Cap: $1.31B